Implications of Being an Emerging Growth Company
We qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth
company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions
- reduced obligations with respect to financial data, including presenting only two years of audited financial statements and only two years of
selected financial data in this prospectus supplement;
- an exception from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the
- reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and
- exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements.
may take advantage of these provisions for up to five years or such earlier time that we no longer qualify as an emerging growth company. We would cease to be an emerging growth
company if we have more than $1.07 billion in annual revenue, have more than $700 million in market value of our capital stock held by non-affiliates as of the end of our second fiscal
quarter or issue more than $1.0 billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of these reduced reporting burdens. For example, we
have taken advantage of the exemption from auditor attestation on the effectiveness of our internal control over financial reporting. To the extent that we take advantage of these reduced reporting
burdens, the information that we provide stockholders may be different than you might obtain from other public companies in which you hold equity interests.
addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have
irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies. Based on our public float as of the date of this prospectus supplement, we currently expect that we will become a large accelerated filer, and cease
to be an emerging growth company, as of December 31, 2017.
Our Corporate Information
We were originally formed under the laws of the state of Delaware in March 2010 under the name BioLife Cell Bank, LLC. In January 2012,
we converted from a limited liability company to a Delaware corporation, BioLife Cell Bank, Inc. In January 2014, we amended and restated our certification of incorporation to change our name
to AveXis, Inc. Our principal executive offices are located at 2275 Half Day Road, Suite 200, Bannockburn, Illinois 60015, and our telephone number is (847) 572-8280. Our website
address is www.avexis.com. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus supplement, and you should not consider any
information contained on, or that can be accessed through, our website as part of this prospectus supplement or in deciding whether to purchase our common stock.